Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2023-04-21 Declaration of Voting R…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.03.23.
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal announcement dated April 21, 2023, detailing the 'Nombre d'actions composant le capital social et nombre total de droits de vote' (Number of shares comprising the share capital and total number of voting rights) as of March 31, 2023. This information is explicitly required by French commercial code (Article L. 233-8 II) and AMF regulations (Article 223-16). This type of periodic disclosure regarding share capital structure and voting rights does not fit neatly into standard SEC filings like 10-K or ER. It is a specific regulatory disclosure concerning ownership structure and voting power. Among the provided definitions, 'Major Shareholding Notification' (MRQ) often covers changes in significant ownership thresholds, but this document is a mandatory periodic statement of the total capital structure and voting rights, which is often categorized under general regulatory updates or specific capital structure disclosures. Given the focus on the total number of shares and voting rights, it is most closely related to disclosures that impact shareholder rights and capital structure reporting. Since there isn't a perfect fit for a mandatory French capital structure disclosure, and it is not a dividend notice (DIV), share issue (SHA), or director dealing (DIRS), it falls best under a general regulatory filing category. However, since it specifically reports on the total voting rights and share count, which is a key component of shareholder structure reporting, and is a periodic regulatory update, it aligns most closely with the intent of disclosures related to share capital changes or major ownership reporting. Given the options, and recognizing this is a mandatory disclosure about the capital base, it is a specific regulatory filing. If we must choose the closest fit among the options, it relates to the structure of ownership/voting rights. Since it is not a transaction (POS, SHA) or a director trade (DIRS), and not a major shareholder crossing a threshold (MRQ), it is best classified as a general Regulatory Filing (RNS) as it is a mandatory, periodic regulatory update that doesn't match other specific categories, or potentially related to capital structure (CAP). Given the context of mandatory periodic reporting on voting rights, RNS is the safest fallback for specific, non-standard regulatory reports. However, if we interpret 'Major Shareholding Notification' (MRQ) broadly as any notification related to share structure/voting rights, it could fit there, but MRQ usually implies crossing a threshold. Since this is a statement of the total, it is a general regulatory filing.
2023-04-21 French
Abivax : résultats annuels 2022 et point d’avancement sur l’activité
Earnings Release Classification · 1% confidence The document is titled "ABIVAX : RESULTATS ANNUELS 2022 ET POINT D'AVANCEMENT SUR L'ACTIVITE" (ABIVAX: 2022 ANNUAL RESULTS AND BUSINESS UPDATE). It explicitly states that it publishes its financial results for the fiscal year 2022 ended December 31st, and includes detailed tables showing the 'Eléments du compte de résultats' (Income Statement items) and 'Eléments du bilan financier' (Balance Sheet items) for 2022 compared to 2021. The text also mentions that the annual accounts have been audited. This content strongly indicates a comprehensive annual financial report. Although it contains operational updates, the core purpose is the presentation of audited annual financial performance, which aligns best with the Annual Report (10-K) definition, even if the company is not US-listed (the definition covers 'Official yearly report covering company activity and full financial performance'). Since the document provides the full annual financial statements and management discussion, it is classified as the Annual Report, not just an Earnings Release (ER) or a Report Publication Announcement (RPA). FY 2022
2023-04-19 French
Abivax reports 2022 financial results and operations update
Earnings Release Classification · 1% confidence The document is titled "Abivax reports 2022 financial results and operations update" and explicitly states it announces the "2022 annual financial results, as of December 31, 2022." It contains detailed financial tables (Income Statement, Balance Sheet items) for FY 2022 compared to FY 2021, discusses operating results, R&D expenses, cash position, and financing activities. This content strongly aligns with the definition of an Annual Report, which is typically filed on Form 10-K in the US context, or the equivalent comprehensive annual filing. Although it is presented as a news release (EQS-News), the substance is the full annual financial performance review. Given the options, 10-K is the most appropriate classification for a comprehensive annual financial results report, even if this specific document is the press release version of those results. The length (over 30k characters) confirms it is not just a brief announcement (RPA/RNS) but the detailed results themselves. FY 2022
2023-04-19 English
Michael Ferguson est nommé Directeur Commercial d’Abivax
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of Michael Ferguson as Chief Commercial Officer (Directeur Commercial) of Abivax, effective immediately. It details his background, responsibilities related to the drug obefazimod, and includes quotes from the CEO and the new appointee. This type of announcement, focusing specifically on changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The filing type code for this is MANG.
2023-04-18 French
Abivax appoints Michael Ferguson as Chief Commerical Officer
Board/Management Information Classification · 1% confidence The document is a press release dated April 18, 2023, announcing the appointment of Michael Ferguson as the new Chief Commercial Officer (CCO) of Abivax. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The keywords 'appoints', 'Chief Commercial Officer', and the focus on executive team changes confirm this classification. It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2023-04-18 English
Abivax annonce les résultats d’efficacité et de tolérance d’obefazimod après deux ans de traitement dans l’étude de maintenance de phase 2b dans la rectocolite hémorragique
Earnings Release Classification · 1% confidence The document is a press release dated April 17, 2023, announcing clinical efficacy and safety results for the drug obefazimod in a Phase 2b maintenance study for Ulcerative Colitis (Rectocolite Hémorragique). It details specific clinical endpoints (remission rates, endoscopic improvement) and includes commentary from management and investigators. This format—a formal announcement of periodic financial/clinical results, often released before a full quarterly or annual report—aligns best with an Earnings Release (ER), which covers key periodic financial/operational highlights. Although it contains detailed clinical data, it is presented as a press release summarizing results, not the comprehensive financial report (10-K or IR). Since it is a release of periodic performance results, ER is the most appropriate classification. FY 2023
2023-04-17 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.